4//SEC Filing
DESOUZA ERROL B 4
Accession 0000950103-20-018598
CIK 0001802768other
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 8:28 PM ET
Size
8.6 KB
Accession
0000950103-20-018598
Insider Transaction Report
Form 4
DESOUZA ERROL B
Director
Transactions
- Award
Class A Ordinary Shares
2020-06-18+8,929→ 44,644 total - Award
LP interests in RPI US Partners 2019, LP
2020-06-15+53,915→ 53,915 total(indirect: By Trust)Exercise: $0.00→ Class A Ordinary Shares (539,150 underlying)
Footnotes (3)
- [F1]The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020.
- [F2]Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.
- [F3]Includes RPI US LP Interests convertible into 39,010 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share.
Documents
Issuer
Royalty Pharma plc
CIK 0001802768
Entity typeother
Related Parties
1- filerCIK 0001213895
Filing Metadata
- Form type
- 4
- Filed
- Sep 22, 8:00 PM ET
- Accepted
- Sep 23, 8:28 PM ET
- Size
- 8.6 KB